Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 99Biopsy 72pembrolizumab 58Carboplatin 55Nivolumab 54Cisplatin 53Cyclophosphamide 51Paclitaxel 41Bevacizumab 36Radiotherapy 33Gemcitabine 33Dexamethasone 30Doxorubicin 25atezolizumab 24Fluorouracil 24olaparib 23Rituximab 23Pemetrexed 23fludarabine 22durvalumab 21Radiation 21Cytarabine 21venetoclax 20Vincristine 20Prednisone 20Oxaliplatin 20Ipilimumab 20Injections 20Lenalidomide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Omacor × 30 days × Clear all
NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

National Cancer Institute (NCI)

Phase 2 Recruiting
66 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡